0      0


ISPT02 - Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB) - Urovant


‐ Mar 4, 2021 1:30pm


Credits: None available.

Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB)
An Overview of OAB Implications and Challenges and a New Treatment Option for Long-Term Care

Supported by Urovant Sciences:  This product theater will discuss the clinical profile and prescribing information for GEMTESA® (vibegron) 75mg tablets, for the treatment of Overactive Bladder. The presentation will also review challenges and implications associated with overactive bladder in long term care.

custom image


Credits

Credits: None available.